Picard Medical Eyes Next-Gen Heart, Faces Going Concern Warning

TL;DR

**PMI is a high-risk bet on a next-gen artificial heart, but the going concern warning makes it a speculative play for only the boldest investors.**

AI Summary

Picard Medical, Inc. (PMI) filed its 10-K for the fiscal year ended December 31, 2025, detailing its operations as a holding company for SynCardia Systems, LLC. SynCardia manufactures and sells the only FDA and Health Canada approved Total Artificial Heart (TAH), with over 2,100 implants across 27 countries. The company is strategically focused on developing the next-generation, fully implantable Emperor TAH, with design prototypes currently undergoing non-clinical testing and potential FDA approval as early as 2028. PMI also aims to expand U.S. commercial adoption by seeking FDA approval for bridge to candidacy (BTC) and longer duration support indications for its SynCardia TAH. Internationally, PMI is pursuing CE Mark certification in the EU and evaluating pathways in China. The company completed an Initial Public Offering (IPO) in September 2025, raising $19.6 million in gross proceeds from 4,887,500 shares at $4.00 per share, with net proceeds of $15.2 million used for operations, R&D, sales expansion, and repayment of approximately $8.2 million in Senior Secured Notes and related party working capital loans. The filing highlights significant risks, including reliance on a limited number of products and customers, complex manufacturing, and the independent auditor's explanatory paragraph regarding PMI's ability to continue as a going concern.

Why It Matters

Picard Medical's 10-K reveals a critical juncture for the medical device company, as it navigates the high-stakes development of its next-generation Emperor TAH while its auditor flags a going concern risk. For investors, this means potential for significant upside if the Emperor TAH gains approval and market traction, but also substantial downside risk given the financial uncertainties and intense competition from larger players like Abbott in the broader mechanical circulatory support market. Employees and customers rely on the continued viability of PMI, especially given its SynCardia TAH is the only FDA-approved option in the U.S. and Canada, making its strategic moves and financial health crucial for patient access to life-saving technology. The broader market will watch closely to see if PMI can overcome its financial hurdles and successfully innovate in the highly regulated and capital-intensive artificial heart sector, potentially disrupting the cardiac care landscape.

Risk Assessment

Risk Level: high — The risk level is high due to the independent registered public accounting firm including an explanatory paragraph relating to PMI's ability to continue as a going concern in its report on the audited financial statements. Additionally, the company is a newly public, emerging growth, and smaller reporting company, facing increased costs to establish effective internal controls and comply with evolving disclosure and governance requirements, which may result in an inability to maintain its NYSE American listing.

Analyst Insight

Investors should approach PMI with extreme caution, recognizing the significant 'going concern' risk highlighted by the auditor. While the potential for the Emperor TAH is compelling, consider this a highly speculative investment and only allocate capital that you are prepared to lose entirely, closely monitoring future financial statements and regulatory progress.

Key Numbers

• $130,820,904 — Aggregate market value of common stock held by non-affiliates (As of September 2, 2025, the IPO closing date)
• 75,178,535 — Common shares outstanding (As of March 23, 2026)
• $19.6 million — Gross proceeds from IPO (From 4,887,500 shares at $4.00 per share in September 2025)
• $15.2 million — Net proceeds from IPO (After underwriting discounts and commissions)
• $8.2 million — Repayment of Senior Secured Notes and related party working capital loans (Using net proceeds from IPO)
• 2,100 — SynCardia TAHs implanted (Across 27 countries to date)
• 2028 — Earliest potential FDA approval for Emperor TAH (Subject to nonclinical testing and regulatory review)
• 4,887,500 — Shares sold in IPO (Including over-allotment options)
• $4.00 — Public offering price per share (For the September 2025 IPO)
• 27 — Countries with SynCardia TAH implants (Demonstrating international reach)

Key Players & Entities

• Picard Medical, Inc. (company) — Registrant and holding company
• SynCardia Systems, LLC (company) — Wholly-owned subsidiary operating business
• FDA (regulator) — Approves Total Artificial Heart
• Health Canada (regulator) — Approves Total Artificial Heart
• Emperor TAH (company) — Next-generation fully implantable artificial heart under development
• NYSE American LLC (regulator) — Exchange where common stock is listed
• MaloneBailey, LLP (company) — Independent registered public accounting firm
• CARMAT SA (company) — Competitor developing Aeson total artificial heart
• BiVACOR Inc (company) — Competitor in early-stage human clinical testing
• Abbott HeartMate 3 LVADs (company) — Alternative mechanical circulatory support device

FAQ

Risk Factors

• Reliance on Limited Products and Customers [high — operational]: The company's operations are heavily dependent on the SynCardia Total Artificial Heart (TAH) and its next-generation Emperor TAH. A significant portion of revenue may be derived from a limited number of customers, such as hospitals and transplant centers. Any disruption in the manufacturing, supply chain, or demand for these core products could materially impact financial performance.
• Going Concern Uncertainty [high — financial]: The independent auditor's report includes an explanatory paragraph regarding the company's ability to continue as a going concern. This indicates substantial doubt about the company's ability to meet its financial obligations in the near future, potentially affecting its access to capital and operational continuity.
• Product Development and Regulatory Approval Risks [high — regulatory]: The development of the Emperor TAH and expansion of indications for the SynCardia TAH (e.g., bridge to candidacy, longer duration support) are subject to complex and lengthy FDA and international regulatory review processes. Delays or failure to obtain necessary approvals, such as the potential FDA approval for Emperor TAH in 2028, could significantly hinder growth prospects.
• Complex Manufacturing and Supply Chain [medium — operational]: The manufacturing of the SynCardia TAH and its components is complex, requiring specialized expertise and adherence to strict quality control standards. Any disruptions in the manufacturing process, supply chain for critical components, or inability to scale production to meet demand could adversely affect the company's ability to deliver products.
• Market Adoption and Competition [medium — market]: While the SynCardia TAH is the only FDA-approved TAH, the company faces competition from other mechanical circulatory support devices and potential future entrants. Expanding U.S. commercial adoption and achieving CE Mark certification in the EU are critical for growth, but market acceptance and competitive pressures could limit revenue.

Industry Context

Picard Medical operates in the highly specialized and regulated medical device market for advanced cardiac support. The Total Artificial Heart (TAH) segment is characterized by high barriers to entry due to complex technology, extensive clinical validation, and stringent regulatory approvals. Key trends include the development of smaller, fully implantable devices and expanding indications for mechanical circulatory support to improve patient outcomes and quality of life.

Regulatory Implications

The company's primary regulatory focus is on obtaining and maintaining FDA and international approvals for its TAH products. The development of the Emperor TAH and expanded indications for the SynCardia TAH are critical growth drivers, but subject to lengthy and uncertain regulatory review processes. Compliance with manufacturing standards and post-market surveillance is paramount.

What Investors Should Do

1. Monitor progress on Emperor TAH development and FDA approval timeline.
2. Assess the company's ability to address going concern risks.
3. Evaluate the success of U.S. commercial adoption and international expansion efforts.
4. Analyze revenue concentration and customer diversification.

Key Dates

• 2025-09-01: Initial Public Offering (IPO) — Picard Medical, Inc. raised $19.6 million in gross proceeds, providing capital for operations, R&D, and debt repayment, and establishing a public market valuation.
• 2028-01-01: Earliest Potential FDA Approval for Emperor TAH — This date represents a key future milestone for the company's next-generation product, which could significantly expand its market opportunity if approved.

Glossary

Total Artificial Heart (TAH)

A medical device that completely replaces the function of a failing human heart, consisting of artificial ventricles and valves. (This is the company's core product, representing its primary revenue stream and market differentiator.)

Bridge to Transplantation (BTT)

A medical strategy where a device supports a patient with end-stage heart failure, keeping them alive and stable until a suitable donor heart becomes available for transplantation. (This is the primary indication for the current SynCardia TAH, highlighting its role in the heart transplant pathway.)

Emperor TAH

The next-generation, fully implantable and driver-less artificial heart being developed by SynCardia. (This represents a significant future growth opportunity for the company, aiming to overcome limitations of current TAH systems.)

Companion 2 Driver (C2 Driver)

An external pneumatic driver used to power the SynCardia TAH system for in-hospital use. (Part of the current TAH system, it is essential for patient support and management.)

Freedom Driver

A portable external pneumatic driver that allows patients implanted with the SynCardia TAH to be discharged from the hospital. (Enables patient mobility and a higher quality of life while awaiting transplant, a key feature of the SynCardia TAH.)

Diagnosis Related Group (DRG) 001

A Medicare reimbursement classification for the highest-paying cardiac procedures, which includes the implantation of a Total Artificial Heart. (Indicates favorable reimbursement rates for TAH implantation in the U.S., supporting hospital adoption.)

Year-Over-Year Comparison

As this is the company's first 10-K filing following its September 2025 IPO, a direct comparison of key financial metrics like revenue, net income, and margins to a prior year's filing is not possible. However, the filing does indicate the use of IPO proceeds to repay $8.2 million in debt, suggesting a deleveraging effort. The primary focus is on the company's current operational status, future growth strategies, and the significant going concern risk identified by the auditor.

Key Financial Figures

• $0.0001 — ch Registered Common stock, par value $0.0001 per share PMI NYSE American LLC Se
• $4.00 — n Stock") at a public offering price of $4.00 per share for total gross proceeds of $
• $19.6 m — 0 per share for total gross proceeds of $19.6 million, before deducting underwriting di
• $15.2 million — an, LLC ("NYSE American"). PMI received $15.2 million in proceeds, net of underwriting discou
• $8.2 million — l plus interest amount of approximately $8.2 million. For more information on the Senior Sec
• $15.0 million — (the "Purchase Agreement"). An initial $15.0 million aggregate principal amount of Senior Se
• $35.0 million — 2025. PMI may issue up to an additional $35.0 million aggregate principal amount of notes in
• $2.675 — n stock at an initial exercise price of $2.675 per share, subject to adjustment as pro

Filing Documents

• pmi20251231_10k.htm (10-K) — 2411KB
• ex_937868.htm (EX-3.3) — 7KB
• ex_937873.htm (EX-4.4) — 36KB
• ex_937867.htm (EX-10.59) — 43KB
• ex_937866.htm (EX-19.1) — 85KB
• ex_938072.htm (EX-23.1) — 3KB
• ex_937871.htm (EX-31.1) — 9KB
• ex_937872.htm (EX-31.2) — 9KB
• ex_937869.htm (EX-32.1) — 5KB
• ex_937870.htm (EX-32.2) — 5KB
• ex_937865.htm (EX-97.1) — 24KB
• adverseevents.jpg (GRAPHIC) — 34KB
• c2bresize.jpg (GRAPHIC) — 109KB
• freedom2resize.jpg (GRAPHIC) — 70KB
• icec01.jpg (GRAPHIC) — 67KB
• tah3resize.jpg (GRAPHIC) — 179KB
• 0001437749-26-010133.txt ( ) — 12606KB
• pmi-20251231.xsd (EX-101.SCH) — 96KB
• pmi-20251231_cal.xml (EX-101.CAL) — 83KB
• pmi-20251231_def.xml (EX-101.DEF) — 646KB
• pmi-20251231_lab.xml (EX-101.LAB) — 614KB
• pmi-20251231_pre.xml (EX-101.PRE) — 692KB
• pmi20251231_10k_htm.xml (XML) — 1695KB

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 16 Item 1B. Unresolved Staff Comments 32 Item 1C. Cybersecurity 32 Item 2.

Properties

Properties 33 Item 3.

Legal Proceedings

Legal Proceedings 33 Item 4. Mine Safety Disclosures 33 PART II. Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 34 Item 6. [Reserved] 34 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 38 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 38 Item 9A.

Controls and Procedures

Controls and Procedures 38 Item 9B. Other Information 38 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 39 PART III. Item 10. Directors, Executive Officers and Corporate Governance 40 Item 11.

Executive Compensation

Executive Compensation 42 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 45 Item 13. Certain Relationships and Related Transactions, and Director Independence 46 Item 14. Principal Accounting Fees and Services 49 PART IV. Item 15. Exhibit and Financial Statement Schedules 50 Item 16. Form 10-K Summary 52

Signatures

Signatures 53 Table of Contents CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K ("Annual Report") contains forward-looking statements which are made pursuant to safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements including, without limitation, statements regarding our business strategy, expected expansion of our research and development, investments, and our operations and expected financial performance and condition. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would," or other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms, although not all forward-looking statements contain these words. Forward-looking statements are based on management's current expectations, estimates, forecasts, and projections about our business and the industry in which we operate, and management's beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Annual Report may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inacc

BUSINESS

ITEM 1. BUSINESS OVERVIEW OF BUSINESS General Picard Medical, Inc. ("PMI") was incorporated in the state of Delaware on April 8, 2021. Unless the context requires otherwise, in this Annual Report, the terms "we," "us," "our," the "Company," "Picard," the "Registrant," and similar references refer to the combined operations of PMI and its consolidated subsidiaries and affiliates, including SynCardia Systems, LLC ("SynCardia"). PMI functions as a holding company and owns 100% of the membership interests of SynCardia. Business operations are carried out by and through SynCardia, and accordingly most of the information in this Annual Report pertains to SynCardia's business. SynCardia is a medical technology company that manufactures and sells the only U.S. Food and Drug Administration ("FDA") and Health Canada approved Total Artificial Heart ("TAH"), which fully replaces the function of a failing human heart. To date, more than 2,100 SynCardia TAHs have been implanted in patients across 27 countries, and the SynCardia TAH is an established bridge to heart transplantation ("BTT") for patients with biventricular heart failure, also referred to as end-stage heart failure, in the United States and around the globe. SynCardia is also pursuing additional research and advancements in medical technology, including the next-generation, fully implantable and driver-less heart, the Emperor TAH. Both the SynCardia and Emperor TAH are subject to additional development and regulatory review. The currently approved SynCardia TAH System consists of an implant including left and right artificial ventricles, external pneumatic drivers that power the implant, and drivelines that connect the external driver to the implant. The implantation procedure follows routine surgical techniques used by cardiothoracic surgeons performing heart transplantation. The system provides immediate and complete cardiac output by replacing both ventricles and all four heart valves. The SynCardia TAH is

View Full Filing

View this 10-K filing on SEC EDGAR